20:07 , Dec 1, 2016 |  BC Week In Review  |  Company News

BromSite sales and marketing update

Sun launched BromSite bromfenac in the U.S. to treat postoperative inflammation and prevent pain during cataract surgery. BromSite consists of low-dose bromfenac, an NSAID, and is delivered via the DuraSite sustained delivery technology from Sun's...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Company News

InSite, Sun Pharmaceutical deal

Sun’s Ranbaxy Inc. subsidiary will acquire InSite for $0.35 per share or about $48 million. The price is a 3% premium to InSite’s close of $0.34 on Sept. 14, the day before the deal was...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

BromSite regulatory update

InSite submitted an NDA to FDA for BromSite to treat inflammation and prevent pain in cataract surgery. BromSite is low-dose bromfenac, an NSAID, delivered via InSite’s DuraSite sustained delivery technology. Last week, QLT Inc....
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

InSite, QLT deal

QLT will acquire InSite in a stock deal. Last week, InSite submitted an NDA to FDA for BromSite to reduce postoperative inflammation and prevent pain after cataract surgery. BromSite is low-dose bromfenac, an NSAID,...
07:00 , Jun 15, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg6/12 clsPlasmaTech Biopharmaceuticals Inc. (NASDAQ:PTBI)Roth Capital PartnersElemer PirosNewBuy0%$7.33 Piros initiated coverage with a $16 target, saying the company is "assembling a world-class gene and protein therapeutics portfolio for...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Company News

InSite, Nicox deal

InSite granted Nicox exclusive rights to develop, manufacture and commercialize AzaSite, BromSite and AzaSite Xtra in Europe, the Middle East and Africa. Nicox expects to submit MAAs for AzaSite and BromSite in...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

3Q14 Financial Markets Preview: Summer lull

With Vertex Pharmaceuticals Inc. already having delivered 2014's most anticipated data and Gilead Sciences Inc. having rolled out the year's most keenly watched launch, buysiders expect a quiet 3Q14 and plan to use the lull...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

BromSite: Phase III data

Top-line data from 234 patients who underwent cataract surgery in the modified intent-to-treat (mITT) population of a double-blind Phase III trial showed that twice-daily BromSite met the primary endpoint of reducing post-surgical ocular inflammation from...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

BromSite: Completed Phase III enrollment

InSite completed enrollment of about 240 patients undergoing cataract surgery in a double-blind Phase III trial comparing twice-daily BromSite vs. the DuraSite vehicle alone. Patients will receive BromSite the day prior to surgery, the day...